Amgen Stock News

Amgen, Inc. (NASDAQ:AMGN ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations James Bradner - EVP, Research & Development Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Courtney Breen - Bernstein Salveen Richter - Gold...

Biotechnology specialist Amgen (AMGN 0.05%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.

Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

THOUSAND OAKS, Calif. , Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The Dow Jones Industrial Average got off to a solid start this year. The widely reported index, consisting of 30 large-cap stocks representing multiple sectors of the economy, gained 4.7% in the first month of the year.

Der US-Biotechkonzern Amgen US0311621009 blickt nach einem überraschend gut verlaufenen Quartal optimistisch in die Zukunft.

The Dow Jones industrial average (DJIA) is a price-weighted average of 30 blue-chip U.S.

THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets.